Targeting CYP450 enzymes offers a promising strategy to enhance cancer therapy. Inhibitors of specific CYP450 enzymes can be used to increase the systemic exposure of chemotherapeutic agents, potentially improving their efficacy. For example, ritonavir, a CYP3A4 inhibitor, is sometimes co-administered with other drugs to boost their levels. Additionally, understanding the CYP450 profile of a patient can help in personalizing treatment regimens to minimize adverse effects and improve outcomes.
